IRADIMED CORPORATION (IRMD)
Nasdaq · Healthcare · Medical Devices
$86.47+1.25%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.1B
- P/E (trailing)
- 48.3
- Forward P/E
- 35.3
- Dividend yield
- 0.9%
- 52-week range
- $70.80 – $107.90
- 52-week change
- +19.01%
- EPS (trailing)
- $1.79
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $83.8M (+14.43%)
- Net income
- $22.5M
- Operating margin
- 31.2%
- Diluted EPS
- $1.75
- Free cash flow
- $17.2M
From the company’s annual report on SEC EDGAR.
About IRADIMED CORPORATION
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
Headquarters: Orlando, United States · 166 employees · iradimed.com